SUMMARY
Invasive fungal infections constitute a serious threat to an evergrowing population of immunocompromised individuals and other individuals at risk. Traditional diagnostic methods, such as histopathology and culture, which are still considered the gold standards, have low sensitivity, which underscores the need for the development of new means of detecting fungal infectious agents. Indeed, novel serologic and molecular techniques have been developed and are currently under clinical evaluation. Tests like the galactomannan antigen test for aspergillosis and the ␤-glucan test for invasive Candida spp. and molds, as well as other antigen and antibody tests, for Cryptococcus spp., Pneumocystis spp., and dimorphic fungi, have already been established as important diagnostic approaches and are implemented in routine clinical practice. On the other hand, PCR and other molecular approaches, such as matrix-assisted laser desorption ionization (MALDI) and fluorescence in situ hybridization (FISH), have proved promising in clinical trials but still need to undergo standardization before their clinical use can become widespread. The purpose of this review is to highlight the different diagnostic approaches that are currently utilized or under development for invasive fungal infections and to identify their performance characteristics and the challenges associated with their use.
INTRODUCTION

R
apid advances in the fields of transplant medicine and cancer treatment, together with the ever-growing implementation of immunomodulatory regimens, have led to a significant increase in the prevalence and prolonged survival of people in immunocompromised states (1) . This change in the epidemiologic trend has led to an increased incidence of opportunistic pathogens, which thrive under these circumstances in patients in transplant and cancer units and also in patients in general medical and surgical wards (2) . Among the various opportunistic pathogens, fungi represent a serious and important threat.
Fungal microbes are abundant in nature and are frequent colonizers on various human mucosal surfaces, where they can live by evading host defenses (3) . However, under conditions of impaired immune responses or a break in host barriers, fungi are able to invade normally sterile areas of the human body, where they can cause severe infections that are difficult to recognize and treat and are often ultimately lethal (3) . Indeed, recent epidemiologic data from various studies show that invasive fungal infections (IFIs) are frequently encountered in clinical practice, with the most common offenders, by far, being Candida spp. and Aspergillus spp.
In order to effectively eliminate these infections, early diagnosis and species identification are of paramount importance. Unfortunately, the current standard diagnostic methods are far from adequate (4) (5) (6) . To overcome this obstacle, many researchers have focused on the development of novel diagnostic approaches, with serologic and, especially, molecular methods currently in the spotlight of such investigations.
The purpose of our review is to provide the reader with comprehensive and up-to-date information on diagnostic methods for IFIs that are currently under development or under investigation, focusing especially on molecular approaches.
CHALLENGES OF VALIDATING DIAGNOSTIC TESTS FOR FUNGAL PATHOGENS
Before implementation into routine clinical practice, and before incorporation into guidelines, every new diagnostic test should go through a lengthy process of validation. Many different analytical aspects of a new test should be evaluated, including the limit of sensitivity, reproducibility, and accuracy and, for quantitative tests, the upper and lower limits of quantification and the linear range. Accuracy can be difficult to determine when there is not a gold standard test or standard material available, which is the case for most tests used in fungal diagnostics. Once the analytical validation is complete, a clinical validation is required to assess the clinical utility of the test. These studies can be challenging to perform due to the limited number of cases of fungal disease that may be seen at any given institution. The need to validate an array of specimen types (whole blood, serum, plasma, bronchoalveolar lavage [BAL] fluid, or urine) further complicates test validation. Other important factors that influence the uptake of a test in the clinical laboratory include the ease of use, cost, and the fact that several of the newer molecular tests are complex to perform, requiring multistep manual methods to purify nucleic acids. Taking these challenges together, it is not surprising that there are a limited number of FDA-cleared fungal diagnostics in routine clinical use.
Unfortunately, when it comes to IFIs, the gold standard tests are far from perfect, as already mentioned. Therefore, the direct comparison of a new diagnostic test to culture-based systems might fail to identify tests that may, in some aspects, perform better than the gold standard. In fact, direct comparison in that case may create a false impression of low specificity of the new test if truly positive IFIs are identified by the new method but fail to be identified by the gold standard. In an effort to overcome this obstacle, the European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) issued definitions for invasive fungal infections to be used for research purposes in 2002 (7) , and these were subsequently revised in 2008 (8) . These definitions take into account results of histopathology reports and standard diagnostic tests, together with imaging findings, predisposing factors, and clinical findings, and separate the research cases into proven, probable, possible, and unlikely IFIs.
However, even after the publication of these definitions, there is still an ongoing debate about the most efficient way to use the criteria in reporting evaluation results. Some researchers argue that by disregarding possible cases and considering only proven and probable cases as truly positive (and unlikely cases as truly negative), one can reach valid conclusions about the performance of a novel diagnostic test (9) . Others prefer to classify possible cases as truly positive, especially when clinical suspicion is high, attesting that by totally disregarding possible cases, it is very difficult to reach significant conclusions, since this considerably limits the number of true-positive cases (10) . These inconsistencies in design between studies conducted by different researchers hinder the possibility of cross-comparisons and valid meta-analyses of different studies and thus create a significant obstacle in the process of widespread implementation of novel diagnostic tests in the field of clinical mycology. Finally, the decreasing rates of autopsies in modern hospitals make the diagnosis of proven IFIs impossible in some cases, thus further confounding the results of observational studies.
NONMOLECULAR METHODS
Nonmolecular diagnostic techniques remain the established practice for diagnosing invasive fungal infections. However, their relatively low sensitivity often leads to considerable delays in diagnosis and initiation of targeted treatment.
Invasive Candidiasis
The diagnosis of invasive candidiasis requires biopsy of the involved tissue, followed by staining, culture, and histopathology. Blood cultures remain the gold standard for the diagnosis of candidemia and should be the initial diagnostic test when candidemia is suspected. However, cultures take 1 to 3 days to grow and an additional 1 to 2 days for identification of the organism, which often leads to considerable delays in initiation of targeted treatment. The impact of such delays in the case of IFIs is vast, with studies showing significant daily increases in mortality and hospitalization costs for every day without appropriate antifungal agents (11) (12) (13) (14) (15) (16) (17) . For example, a study by Morrell and colleagues evaluated the delay in treatment due to the time required for diagnosis as a mortality risk factor for invasive Candida sp. infection. Their analysis found that administration of antifungal treatment 12 h after the first blood culture sample that tested positive was drawn was an independent determinant of hospital mortality (odds ratio [OR] ϭ 2.09; P ϭ 0.018) (13) . Bactec 9240 and Bac/T Alert are the most commonly used blood culture systems for the detection of Candida spp. (18) . The average time to detection for these systems ranges from 14 to 38 h, may take up to 72 h, and varies depending on the culture conditions used (most Candida spp. grow better in aerobic than in anaerobic bottles) and on the number of circulating cells (19) . Notably, it is still unclear whether the use of dedicated fungal cultures via an isolator collection system can improve the diagnostic yield in cases of fungemia (20) .
The ␤-glucan assay is a useful adjunct, especially for patients with intra-abdominal infections, where the sensitivity of cultures is decreased. ␤-D-Glucan is a major component of the fungal cell wall that is found in sera of patients suffering from many different fungal infections, including invasive candidiasis, invasive aspergillosis (IA), invasive fusariosis, and Pneumocystis jirovecii infection, and thus is not specific. Also, dialysis filters made from cellulose are reported to significantly increase serum ␤-glucan concentrations, leading to false positivity of the test (21) . A multicenter study which included 107 patients with proven candidiasis evaluated the positive predictive value (PPV) of the ␤-D-glucan assay in relation to the cutoff value used. The test's PPV was 83.8% when a cutoff value of 60 pg/ml was used, compared to 89% when a cutoff value of 80 pg/ml was used (22) . Another study suggested the use of this assay for the diagnosis of catheter-associated candidemia by showing that ␤-D-glucan was 4 to 10 times more abundant in biofilm than in planktonic conditions (23) . Several studies have investigated the performance of ␤-glucan assay for the diagnosis of IFIs in patients with hematologic malignancies. The ␤-glucan test has been associated with a large number of falsepositive results in this population and is not considered appropriate for screening purposes and thus for the selection of patients that need preemptive antifungal therapy (24) . The sensitivity of the assay is lower for this population than for noncancer patients, likely due to the higher rates of colonization of these patients with multiple fungi and bacteria that can affect the test results (25, 26) . A recently published meta-analysis which included more than 1,770 patients with hematologic malignancies showed that the performance of 2 consecutive ␤-glucan tests has an excellent specificity (98.9%) but a low sensitivity (49.6%) for the diagnosis of invasive fungal infections (27) .
The Candida albicans germ tube antibody (CAGTA) assay is based on the detection of antibodies against the surfaces of C. albicans germ tubes by indirect immunofluorescence (28) (29) (30) (31) and has a sensitivity of 77 to 89% and a specificity of 91 to 100% (28, 32) . A study published in 2009 by Zaragoza et al. showed that intensive care unit (ICU) patients with a CAGTA-positive assay had lower mortality than patients with a negative assay, likely due to the administration of the appropriate empirical treatment in this group of patients (33) . A more recent study, published in 2011 by the same group, suggests that the CAGTA assay is not affected by Candida colonization or intake of antifungal agents, which makes it particularly useful in the ICU setting (34) . In an effort to establish the position of this test in routine clinical practice, Leon et al. introduced a new diagnostic tool for invasive candidiasis in 2011, based on positive CAGTA and ␤-glucan assays (35) . Finally, other serologic tests for candidemia are the mannan antigen and anti-mannan antibody tests. The combination of a positive mannan test and a positive anti-mannan antibody test has a sensitivity of 73% and a specificity of 80% for the diagnosis of invasive candidiasis in patients with neutropenic fever. The high negative predictive value of 95% suggests the use of the test for exclusion of the disease in this population (36) .
In general, the sensitivity of antibody assays is limited for immunocompromised patients, who are at high risk for becoming infected by invasive candidiasis, since this population often cannot develop antibodies against Candida antigens. Also, the specificity of these assays is limited by the fact that Candida species are part of the normal flora.
Invasive Aspergillosis
The diagnosis of invasive aspergillosis is proven by demonstration of the fungal hyphae in tissue biopsy specimens. The sensitivity of culture for the diagnosis of aspergillosis is low and depends on the population tested. In two recently performed studies, among transplant recipients with a positive molecular test for invasive aspergillosis, only 25 to 50% had a positive culture result (37, 38) . However, a recent study, published in 2005, suggested that incubation of cultures at 35°C leads to a 31% increase in sensitivity compared to incubation at 25°C, which suggests that attempting to mimic physiologic conditions may improve the yield of cultures (39) . Also, the positive predictive value of culture depends on the prevalence of the infection, and thus it is higher among immunocompromised patients and in areas of endemicity. For example, in a study that assessed the positive predictive value of sputum or BAL fluid cultures for different patient populations, the positive predictive value was 72% for hematopoietic cell transplant (HCT) recipients, patients with hematological malignancies, and granulocytopenic patients, 58% for solid organ transplant recipients and patients receiving steroids, and only 14% for patients with HIV infection (40) . In the same study, the PPV was highest for BAL fluid cultures, likely because patients are more likely to have an invasive fungal infection when there are radiographic findings that require bronchoscopy. As a general rule, isolation of Aspergillus spp. from sputum almost invariably represents colonization in immunocompetent patients, while it suggests invasive disease in the setting of a suppressed immune response (41) . Therefore, repeated isolation of the same Aspergillus spp. or alternative diagnostic tests for invasive aspergillosis should be sought to accurately interpret a positive finding, especially in the absence of host factors (42) . However, in the case of critically ill patients, an Aspergillus sp.-positive culture result portends a poor prognosis irrespective of colonization or active infection (43) . Finally, we note that the yields of blood cultures for invasive aspergillosis are very low and thus have a low value even for individuals at high risk (44) . Another disadvantage of cultures is the delay in identifying the species, especially those that are slow to sporulate, which may delay the selection of the appropriate antibiotic (45) .
Histopathology has the advantage of detecting both the invasion of various tissues by fungi and the host response or tissue necrosis. It is almost always performed in conjunction with cultures and improves their positive predictive value by confirming positive culture results. Thus, direct tissue stains are often used to clarify if a positive culture is the result of infection, colonization, or contamination. Aspergillus species can be seen by Gomori methenamine silver or periodic acid-Schiff (PAS) staining. Most tissue stains are inexpensive and can be performed easily in various specimens, such as sputum, BAL fluid, aspirates from lesions, cerebrospinal fluid (CSF), and other tissues (46, 47) . Fungi are identified based on size and morphological characteristics, which are generally nonspecific, thus allowing only for a descriptive diagnosis (48) (49) (50) . Stains do not always allow for accurate identification; for example, Aspergillus spp., Fusarium spp., and Scedosporium spp. all appear as septate, narrow-angle-branching hyphae. Moreover, tissue stains do not allow for identification of the fungus to the species level, which is often needed for treatment. On the other hand, value can be added to the diagnosis by providing clinicians with information about the infecting cell morphology and the state of infected tissues. Furthermore, with the use of advanced microscopy techniques, direct tissue examination and visualization of the infection site have the potential to inform clinicians if a fungal biofilm has formed, a condition that is known for its resistance to commonly used antifungal regimens.
The ␤-D-glucan assay is often useful in combination with culture. Overall, the sensitivities of ␤-D-glucan testing in individual studies have ranged from 55% to 95%, and specificities from 77% to 96%, for patients with hematologic malignancies who are suffering from invasive aspergillosis (22, 25, (51) (52) (53) (54) . Note that the specificity of this test is lower among certain patient populations, such as dialysis recipients and individuals with concurrent Gramnegative bacterial infections (55) (56) (57) . For example, when the reactivities of different bacterial cultures were tested using the Fungitell assay, bacterial ␤-D-glucan of Pseudomonas aeuroginosa cross-reacted with the assay, resulting in false-positive results for patients with bacteremia and no fungemia (58) . Finally, although different ␤-glucan assays have different optimal cutoff values to define positivity, the data from existing clinical studies for the Fungitell assay (the most widely used assay) suggest that the use of a cutoff of 80 pg/ml is associated with better accuracy, while a result of 60 to 80 pg/ml is considered indeterminate, since higher cutoffs significantly decrease the test's sensitivity, although they increase the specificity of the assay (27, 53, 59) .
The galactomannan (GM) assay is a fairly specific and sensitive test for the diagnosis of invasive aspergillosis, although galactomannan can also be found on the cell walls of Histoplasma capsulatum and Fusarium spp. (60, 61) . It can be performed in serum, BAL fluid, CSF, or pleural fluid. Its specificity and sensitivity vary from 40 to 100% and are greatly dependent on the population tested (26, 62) . Specifically, previous antibiotic treatment decreases the specificity of the test, while an antifungal regimen decreases its sensitivity. In addition, the type of antifungal agent affects the performance of the test, and caspofungin has been associated with a higher sensitivity than that with other antifungal agents (26) , likely due to the increase in galactomannan levels after treatment with caspofungin (63) . Note that the test has the highest sensitivity among patients with hematological malignancies or those who have undergone hematopoietic cell transplantation compared to those who have undergone solid organ transplantation or immunocompetent patients (64, 65) . In addition, the sensitivity of the test varies depending on the species and is higher for patients with non-fumigatus aspergillosis than for patients with aspergillosis caused by Aspergillus fumigatus (26) . Also, the performance of the test depends on the immune response of the host as well as the pathogenesis of the disease, with its sensitivity being lower for patients treated with steroids than for neutropenic patients (66) . This might be explained by different progressions of the disease between these 2 types of patients, as shown by a study performed in rabbits. Specifically, neutropenic rabbits had more hyphae than steroidtreated rabbits (67) . Thus, patients with invasive aspergillosis who have been treated with steroids are more likely than neutropenic patients to have a false-negative result (66) .
The sensitivity of the galactomannan test is considered higher when performed with BAL fluid than when performed with serum, with a cutoff value of 1, and a relationship between serum galactomannan, but not BAL fluid galactomannan testing, and mortality of hematopoietic stem cell transplant patients has been described (68, 69) . Other studies have also suggested the use of the galactomannan test as a predictor of all-cause mortality (69, 70) . Since its sensitivity increases even more with sequential testing, it is often used in combination with culture for the definitive diagnosis of a fungal infection (71) (72) (73) (74) . False-positive results for BAL fluid may represent simple colonization of the airways by fungi, more often in lung transplant recipients, or contamination, but this does not significantly affect the specificity of the assay, which remains above 95% (71) . Because performance may depend on the amount of BAL fluid tested, protocols for the application of the technique should be established. Although the galactomannan test has been used for a long time, the optimal cutoff for a positive result has yet to be determined, with some studies showing that a lower cutoff value of 0.5 versus 1 compromises specificity and thus should be avoided (73) , while others suggest that the highest accuracy is achieved by selecting the lower cutoff value and testing consecutive samples (75, 76) . This disagreement is reflected in the latest EORTC guidelines, which avoid recommending a specific cutoff and leave the onus to the manufacturer of the test (8) . It is noteworthy that galactomannan assay is often used to monitor the response to treatment (64) , as it is positive more frequently for patients who fail antifungal treatment (63) . Galactomannan assay with serum but not BAL fluid may have prognostic value, according to a recent study by Fisher et al. which showed that higher serum galactomannan levels were associated with higher respiratory mortality in allogeneic HCT recipients (69) . Note that the use of BAL as a diagnostic intervention in general has provoked some debate recently, due to the wide inconsistencies in the diagnostic yields reported by different operators, which is particularly problematic in the case of high-risk patients, who are frequently colonized or infected by multiple microbial species. A method that could help to reduce these inconsistencies without adversely affecting the diagnostic yield or the complications from the procedure would be the use of a standardized method to perform BAL, as shown by a large prospective study (77) .
Lateral-flow devices (LFDs), which do not require any technical expertise, were recently shown to be more accurate than the standard serologic markers. Their excellent clinical performance and the fact that they can be performed easily and quickly suggest their use as point-of-care (POC) tests (78) . In 2008, Thornton et al. introduced an LFD which detects a glucoprotein antigen in the sera and BAL fluid of patients with invasive aspergillosis in 15 min. This antigen, which is secreted during active growth of A. fumigatus, binds to a monoclonal antibody used to perform the assay and has increased specificity and sensitivity compared to the Fungitell and Platelia GM assays (79) (80) (81) . However, since the interpretation of LFD test results is somewhat subjective, they are useful for the confirmation or exclusion of invasive aspergillosis in combination with other tests, such as PCR (78) . Finally, a recent study published by Held et al. showed that an LFD has a better clinical performance than that of galactomannan assay when used as a screening test rather than a confirmatory test (82) .
The use of electronic noses (E-noses), which assess volatile organic compounds (VOCs), was recently suggested for the diagnosis of invasive aspergillosis, as a diagnostic tool with a high accuracy (90.9%) (83) . Recent studies have shown that patients with invasive aspergillosis exhale a specific VOC, which can be used as a biomarker for the development of fast and cheap diagnostic techniques (84, 85) . Further studies are required to validate such easy-to-use techniques.
Other Fungal Infections
Pneumocystis jirovecii is an opportunistic fungal pathogen that causes severe lung disease to patients at risk. Various diagnostic methods performed on several different specimens have been proposed for the diagnosis of this infection (86) . Older techniques rely on the visualization of Pneumocystis cysts or trophozoites by use of various stains (methenamine silver, toluidine blue, and calcofluor white) on expectorated or induced sputum specimens or on more invasive specimens, such as BAL fluid or lung tissue biopsy specimens. Alternatively, simple imaging with a chest X-ray has been proposed as a diagnostic method. Apart from chest Xray, which has a questionable performance as a sole diagnostic test due to low specificity, all the other methods have high specificities, which often reach 100%. However, their sensitivities vary greatly, from 33% to 100%, depending on the stain and the specimen used. Because Pneumocystis cysts preferentially affect the alveolar space, expectorated sputum is the least accurate specimen, while BAL fluid is the best (87) . Importantly, though, in choosing among different diagnostic practices, one should also consider the cost associated with their utilization, especially for evaluating diseases that preferentially affect populations of lower socioeconomic status, such as opportunistic infections. To address this issue, Harris et al. performed a cost-effectiveness analysis to compare the different diagnostic techniques for Pneumocystis pneumonia (PCP) (86) . Their results indicate that toluidine blue staining of induced sputum samples is the most cost-effective among the staining methods, while the performance of BAL greatly increased the cost of each method, without significantly affecting the percentage of people successfully treated. A newer serologic method that was not involved in the previous analysis and that deserves to be mentioned is the ␤-glucan assay (88) . A recent meta-analysis indicated that ␤-glucan assay performed on serum has a sensitivity and specificity of 94.8% and 86.3%, respectively, for the diagnosis of Pneumocystis pneumonia (89) , while a large retrospective cohort showed that a positive ␤-glucan test correlates well with BAL fluid fungal loads (90) . Therefore, ␤-glucan assay can be an excellent screening tool to rule out the disease in at-risk populations (88) , while additional confirmatory tests are necessary because of the high rate of false-positive results (90) . Furthermore, a prospective study involving 147 patients suspected of having Pneumocystis jirovecii infection showed that ␤-glucan assay is valuable for discriminating definite and probable infections from colonization (91) . On the other hand, a recent study on the kinetics of the test showed that it is not useful as a predictor of a positive response to treatment, as decreases in ␤-glucan values lag significantly behind clinical improvement (92) .
Cryptococcus spp. are known to affect primarily immunocompromised individuals, such as people with HIV infection, with the exception of Cryptococcus gattii, which is notorious for its ability to cause disease in immunocompetent patients (93) . The main characteristic of all Cryptococcus spp., which is the basis for the majority of current diagnostic tests, is the polysaccharide capsule, which contains the glucuronoxylomannan antigen. Cryptococcal meningitis, the most common presentation of cryptococcal disease, is diagnosed primarily with CSF cultures, which grow creamcolored mucoid colonies within 3 to 7 days. However, this delay from suspicion to diagnosis is often unacceptable in the case of such a serious infection, and therefore, alternative screening tests that allow for timely treatment initiation are often performed as adjuncts to culture. Perhaps the oldest method that is still used in clinical laboratories involves staining of the CSF with India ink, which allows visualization of the cryptococcal cells under the microscope, as round, encapsulated yeast organisms, in more than 75% of patients (94) . The most accurate screening method, however, is the cryptococcal antigen test. The test has a high sensitivity and specificity when performed with CSF (97% and 93 to 100%, respectively), while it also has the advantage that it can be performed on serum, with acceptable sensitivity (87%), when CSF is not available (95) . False-positive findings have been reported in cases of Trichosporon sp., Capnocytophaga sp., or Stomatococcus sp. invasive infections (96) . Thanks to its superior performance, the cryptococcal antigen test was included as a method of cryptococcal meningitis diagnosis in the latest EORTC/MSG guidelines. Latex agglutination testing and enzyme immunoassay (EIA) are both widely used methods for cryptococcal antigen detection, with a high concordance between them, although latex agglutination tends to give more false-positive results, especially at low titers (95) . A newly developed method to detect cryptococcal antigen utilizes a lateral-flow immunoassay and has demonstrated a performance comparable to those of EIA and latex agglutination on both CSF and serum (97) . Its low cost, ease of use, high accuracy, and ability to be performed on both serum and urine make it very promising as a point-of-care diagnostic method in settings with limited resources (98) . This becomes particularly important when one considers that antiretroviral treatment alone is insufficient for the management of HIV-infected individuals with CD4 counts of Ͻ100 cells/l who are positive for cryptococcal antigen (99) . Therefore, for these populations, a rapid point-of-care screening test for Cryptococcus spp. can prove to be lifesaving (99) . Finally, we note that while the ␤-glucan antigen test is useful as a screening method for most fungal infections, Cryptococcus spp. are among the exceptions (55) . Therefore, this test is not recommended in this context.
The dimorphic fungi Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidioides immitis share many similar characteristics in morphology and the clinical picture of the infections that they can cause. Microscopic examination followed by culture of the infected tissue is the primary diagnostic method. However, the sensitivity of histopathology is limited, and cultures can take up to 30 days to give a positive result, thus rendering them confirmatory. Therefore, there is a growing body of literature on alternative methods to diagnose these fungal infections, focusing primarily on antigen-antibody tests (Table 1) . Indeed, antibody tests that use complement fixation (the most common) or immunodiffusion are available for Histoplasma spp., although their sensitivities are not ideal (75% for disseminated cases and 66.7% for acute pulmonary histoplasmosis) (100) . Similarly, in the case of blastomycosis, antibody tests have low sensitivities, although immunodiffusion is more sensitive and specific than complement fixation (101) . On the other hand, antigen tests are available for both of these fungal infections, can be performed on both urine and serum, and have superior sensitivities (83.3 to 91.8% for histoplasmosis and 92.9% for blastomycosis) (100, 101) . Also, a recent study showed that H. capsulatum antigenemia, but not antigenuria, decreases rapidly after clearance of the infection in AIDS patients with disseminated disease, thus having the potential to be used to monitor the response to treatment (102) . Note that the H. capsulatum antigen test has a high sensitivity for both AIDS patients and patients with other causes of immune deficiency, such as solid organ transplant recipients (103), while its sensitivity for nonimmunocompromised individuals is relatively lower in cases of disseminated histoplasmosis (100). Importantly, cross-reactivity of these antigen tests seems to be a problem, and although they are specific when tested against nonfungal pathogens, they cannot differentiate between H. capsulatum, B. dermatitidis, and C. immitis, despite the fact that the antigen level is generally higher in cases of disseminated histoplasmosis than in cases of other endemic mycoses (104) . A novel antibody EIA for blastomycosis was recently developed and has a high sensitivity (87.8%), with the additional benefit of being highly specific for B. dermatitidis, showing 94% specificity in patients with histoplasmosis (105) . Serologic tests for coccidioidomycosis include traditional complement fixation and tube precipitin antibody detection methods, which are both commonly employed as diagnostic tests due to their high levels of accuracy. A novel enzyme immunoassay for C. immitis antibody was recently developed and is promising (sensitivity of 95.5% and specificity of 98.5%) (106) . However, the interpretation of a single positive IgM value can be different depending on the pretest probability, and false-positive results have been reported for asymptomatic individuals (107) . Finally, we note that with the exception of blastomycosis, the ␤-glucan antigen test can also have value as a screening method for these fungal infections (108) .
It is evident that antigen-antibody detection methods are available for all the aforementioned fungal infections and have proven to be particularly useful as methods to either "rule in" or "rule out" the infection and to initiate targeted antifungal therapy in a timely manner. However, other infections, such as mucormycosis, fusariosis, and scedosporiosis, still do not have any available antigen-antibody methods that could be helpful. Specifically, mucor-mycosis is diagnosed mainly based on histopathology and cultures and requires a high index of suspicion (109) . Interestingly, in a case series of a rare outbreak of cutaneous necrotizing mucormycosis, all cases were either culture or histopathology positive (110) . Note that ␤-glucan testing has proven to be of little help in cases of Mucor sp. infections (55) . Thankfully, in contrast to the case for invasive aspergillosis, blood cultures have proven to be useful in cases of other invasive mold infections, such as fusariosis (111) and scedosporiosis (112), but not for infections with rarer saprophytic molds (113) . Also, Scedosporium sp. cultures tend to be more reliable for patients with hematologic malignancies than for patients with solid tumors (112) . 
Latex agglutination testing
Latex beads coated with antibodies are mixed with the patient sample. If the antigen is present in the sample, the antibodies will attach to the antigen and agglutination will occur. Testing of serial dilutions of the sample can give a quantitative measure of the amount of antigen present.
Cryptococcal antigen detection.
Enzyme immunoassay Direct
The patient's sample is spread on a plate, and time is allowed for the antigen to adhere to the plastic through charge interactions. An antibody with an enzyme conjugate that changes color after addition of a substrate is added to the patient's sample. If the antigen is present, the antibodies attach and a color change is detected through optical density measurement.
Coccidioides sp. and Blastomyces sp. antibody detection; Histoplasma sp., Blastomyces sp., and Cryptococcus sp. antigen detection. Also, the galactomannan antigen test uses sandwich immunoassay technology. Indirect
The patient's sample is added to a mixture that contains a specific antigen. If antibodies are present in the sample, they will attach to the antigen. Subsequently, antibodies with an enzyme conjugate that bind the primary antibodies are added to the mixture. Color change is detected by optical density measurement.
Sandwich
Same as direct EIA, with the exception that the plate already contains a capture antibody that binds the target antigen, so no charge interactions are necessary.
Immunodiffusion
An agarose gel is prepared with wells cut into the gel. The patient's sample is placed in the center well, and the control antigens or antibodies are added to the outside wells. If the target antibodies or antigens are present in the tested sample, they will form precipitin lines by interacting with the control antigens or antibodies, respectively.
Histoplasma sp. and Blastomyces sp. antibody detection.
Complement fixation
The patient's sample is isolated and heated to destroy all existing complement proteins. Standardized complement proteins and a specific antigen or antibody are added to the sample. Sheep red blood cells (sRBCs) prebound with anti-sRBC antibodies are added to the mix. If the target antibodies or antigens are present in the sample, they will bind the added antigen or antibody and form complexes, which will react with and deplete the complement proteins and salvage the sRBCs. If not, the complement proteins will lyse the sRBCs, thus changing the color of the mix.
Histoplasma sp., Blastomyces sp., and Coccidioides sp. antibody detection.
Lateral-flow assay
The technology is based on a series of capillary beds on an element that can spontaneously transport fluid. The patient's sample is added to the first bed. This soaks up all the extra fluid. The remains are transferred to the second bed, which contains antibodies with an enzyme conjugate that bind antigens or antibodies in the tested sample. The antigen-antibody complexes then move to a third bed, which has capture antibodies that bind the complexes. An additional bed binds only the control antibodies without the antigen, thus serving as a control to ensure that the method worked properly.
Point-of-care diagnostic tests for Cryptococcus sp. and Aspergillus sp. antigen detection.
Immunofluorescence assay (IFA)
The methodology is very similar to that for enzyme immunoassay, but instead of antibodies with an enzyme conjugate, this assay utilizes fluorescein-labeled antibodies which can then be visualized under a fluorescence microscope. It can be performed as both direct and indirect assays.
CAGTA a assay is an indirect IFA.
G test
The G test is specific to beta-glucan detection. Factor G is a proclotting factor that is highly sensitive to beta-glucan. When a patient's sample containing beta-glucan is added to a mix containing factor G, it activates the factor, thus initiating an enzymatic cascade that results in a color or optical density change of the mixture, which can be detected with colorimetric or turbidimetric methods.
Beta-glucan detection.
a CAGTA, Candida albicans germ tube antibody. Each of the nonmolecular assays (cultures, histopathology, and biomarker assays) provides a piece of information to aid clinicians with diagnosing fungal infections ( Table 2) . Taking into consideration that IFIs are difficult to diagnose and that any delay in treatment initiation could lead to a steep rise in mortality rates, newer diagnostic assays with high negative predictive values, such as ␤-glucan or galactomannan assay, should be evaluated in clinical decision algorithms for the ability to serve dual purposes. They could be used to rule out the disease and decrease empirical antifungal use in high-risk populations without other radiologic or microbiologic signs of an IFI, or they could have value as methods to justify stopping presumptive antifungal treatment already initiated in a patient who shows sequentially negative biomarkers for the disease. The combined use of multiple diagnostic assays may increase the accuracy of diagnosis, but at a higher cost; therefore, the cost-effectiveness of each diagnostic strategy should be evaluated further (114) .
MOLECULAR METHODS
Given the rapid and significant advances in cell biology, a series of new diagnostic techniques aiming at identifying the unique molecular fingerprint of each pathogenic microorganism came into use in infectious disease diagnostics and soon became widely available and extremely efficient for diagnosis of certain diseases, such as viral infections. Indeed, molecular methods, the most important of which is PCR, are used every day in routine clinical practice and have replaced traditional diagnostic procedures for a variety of human infections (115) . Their simplicity, ease of use, and short turnaround time are among their most important advantages over traditional techniques. Therefore, it is not surprising that these methods have for years been in the spotlight as a potential solution to the problem of IFI diagnosis (116) .
PCR
The sensitivity of molecular methods raises the possibility of identifying an infection at a very early stage, when it is easier to treat or even completely prevent its clinical manifestation. PCR is one of the oldest and most widely used molecular methods in fungal diagnostics. A major drawback of all traditional PCR techniques initially developed as potential fungal diagnostic tests is that they do not quantify the amount of amplified DNA. Therefore, there is no reliable way to identify the microbial burden within the human body. When it comes to IFIs, this becomes very significant, as fungi are frequent colonizers of human surfaces, and this makes it impossible to determine if the identified fungal DNA is the result of the colonization or does in fact represent an active infection (117) . A solution to the problem was given by the development of real-time PCR techniques. As the name suggests, real-time PCR is able to quantify the amount of amplified DNA in real time (118) . As a result, real-time PCR techniques have largely replaced conventional PCR methods in clinical laboratories.
Despite the great potential of PCR methods, several technical issues associated with their use for fungal DNA isolation create significant discrepancies between different assays and impede efforts toward standardization. More specifically, fungal organisms, and especially molds, have strong cell walls that are particularly difficult to lyse, thus requiring complex and cumbersome methods for DNA isolation (119) . Examples of lysis techniques utilized are enzymatic digestion processes that often rely on use of toxic chemicals, such as phenol-chloroform, mechanical disruption using glass beads, and sonication (120) . In an effort to overcome this barrier, automated extraction methods have been developed that are able to decrease the time for sample processing and lessen the possibility of errors (121) . However, it is still unclear whether these techniques alone adequately disrupt the fungal cell wall and significantly improve the sensitivity of fungal PCR assays (121, 122) . Another problem associated with fungal PCR is the potential for contamination. Fungi are ubiquitous in the environment and can easily contaminate surfaces and materials used in all steps of fungal PCR, including commercially available reagents (123) and collection tubes (124) . Therefore, careful precautions and highly experienced personnel are necessary to avoid false-positive findings associated with contaminants. Another challenge is the choice of the best sample to evaluate the new tests. For example, the significance of Aspergillus sp. isolation from sputum samples is difficult to ascertain for critically ill patients, as it can be hard to differentiate between colonization and chronic infection (41) . Furthermore, without international standards, it is difficult to assess the agreement of quantitative data from different tests and thus to determine the clinical significance of various levels of fungal DNA. Finally, the choice of primers is another important factor that could alter the diagnostic performance of PCR tests for IFIs (Table 3) .
Due to the aforementioned issues, no single test has yet provided enough evidence of its accuracy to be incorporated into guidelines, and thus PCR is not yet widely used in the diagnosis of IFIs (95, 125) . In order to understand the details behind this fact, and given the wide variety of fungal infections, with different characteristics and problems associated with each, it is best to study every disease separately.
IA. Many different PCR assays have been developed over the years for invasive Aspergillus sp. infections. However, clinical reports of their sensitivities and specificities range considerably, from 43 to 100% and 64 to 100%, respectively (9, 10, 52, 72, 126-168). Table 4 lists clinical studies evaluating Aspergillus sp. PCR on various clinical specimens, with comments on special characteristics of each study. There are many reasons behind the obvious variability between different clinical trials, including but not limited to the choice of primers, the method for identification of the amplified DNA, the clinical specimen on which the PCR was performed, and the method of DNA isolation prior to the amplification process. Indeed, while most PCR methods studied so far use primers to amplify sequences within the rRNA genes of Aspergillus spp. (118, 130, 148, 169) , there are some studies that have effectively described amplification of mitochondrial DNA of the fungus (127, 135, 146, 147) . However, even within the rRNA genes selected for amplification, there are multiple different options, such as the 18S ribosomal DNA (rDNA) (72), the 28S rDNA (170) , and the 5.8S rDNA (10), as well as internal transcriber regions between these genes (10, 145) . Although a clinical study evaluating mitochondrial and rRNA gene PCRs on serum samples showed no significant difference between the methods and suggested that the use of both methods could increase the sensitivity of the test (160), a different multicenter evaluation showed that use of mitochondrial primers on serum samples can undermine PCR performance by decreasing its sensitivity (171) .
An additional reason for inconsistencies between results reported from various studies is the different ways used to define PCR positivity. Some investigators prefer to report sensitivity and specificity values, using only one positive result per patient tested (162, 167) . However, others argue that this method significantly decreases the specificity of the results, thus decreasing their clinical value, while it is preferable to define cases that have at least two positive PCR results as "PCR positive" (152) . A recent meta-analysis of 16 studies evaluating PCR assays for Aspergillus spp. in blood specimens found that two positive PCR results had the same sensitivity but superior specificity compared to a single positive result (172) . Nevertheless, more head-to-head comparison studies between the two approaches are needed before a conclusion can safely be reached.
Another ongoing debate revolves around the sample type on which PCR is performed. Many different researchers have tried to determine whether whole-blood, serum, or plasma specimens are better for PCR testing for Aspergillus spp. In the oldest among those studies, Loeffler et al. found that PCR performed on whole blood has a higher sensitivity than PCR performed on plasma, although the two methods have the same lower detection limit (173) . Note that the use of anticoagulants in plasma can significantly deteriorate the sensitivity of the PCR assay by inhibiting the enzymes used in the amplification process and that the greatest inhibition is observed by using heparin or sodium citrate as an anticoagulant (174) . As a result of these differences, researchers who used plasma samples from 96 patients at risk for IA to prospectively test the performance of a real-time PCR assay reported a sensitivity of 55%, whereas the sensitivity of galactomannan testing on the same samples was 100% (52) . A similar question that has been studied more thoroughly is the choice between serum and whole blood. The use of serum is expected to produce fewer false-negative results due to the smaller amount of host DNA that it contains, which is known to compete with the microbial target for amplification (156) , while it will theoretically adversely affect the sensitivity due to the fact that it misses the fungal cell-associated DNA. However, two recent studies evaluating the performance of serum versus whole-blood real-time PCR assays for patients at risk for IA and negative controls failed to find significant differences between the specimens (162, 165) . The reason might be that most of the circulating Aspergillus sp. DNA exists in the form of free DNA that is released after fungal cell breakdown and can be found in both serum and whole blood (175) . Notably, though, in one of the two studies, there was a trend for PCR testing of whole blood to be more sensitive and to be positive earlier than that of serum (165) . An important point to consider is that the volume of serum used to extract DNA might play a decisive role in the accuracy of subsequent PCR, as shown by a study evaluating spiked serum samples (171) . This report was in agreement with a previous study by Suarez et al., who prospectively investigated serum samples from 124 patients with hematologic malignancies and found that the use of a larger serum volume (100 l versus 1 ml) improved the sensitivity from 76.5% to 100%, without altering the specificity of the assay (155) . Therefore, studies using smaller serum volumes to extract DNA might in fact underestimate the performance of a PCR assay on this sample. Furthermore, serum has the advantage of being easier to process, by avoiding cumbersome purification and DNA isolation procedures associated with the use of whole blood, which carry a high risk of contamination, and can also be used to run multiple different tests (PCR, galactomannan, and ␤-glucan assays). Thus, if the aforementioned reports are true and the differences among these specimens are minimal, serum has the potential to become the preferred specimen for PCR testing. Note that an important and often underestimated source of contamination of blood samples tested with Aspergillus sp. PCR that can undermine the test's performance by creating false-positive findings is the blood collection tube, as proved by a recent article which showed that up to 18% of blood collection tubes can be contaminated with Aspergillus sp. DNA (124) . Thus, the use of specialized, contaminant-free means of collecting blood samples might be able to improve PCR performance. BAL fluid has also been used for Aspergillus sp. PCR testing, with promising results. Indeed, results from experimental models of IA show that real-time PCR assays on BAL fluid have sensitivities of Ͼ80%, comparable to that of BAL fluid galactomannan assay (176) . In clinical studies, the overall ranges of sensitivity and specificity varied widely and were 36 to 100% and 70 to 100%, respectively (72, 138, 145, 148) . A recent meta-analysis evaluated the performance of BAL fluid PCR for IA and reported an average sensitivity and specificity of 91% and 92%, respectively (122) . This tendency of average sensitivity to be skewed significantly toward higher values is a reflection of the distribution of the individual studies in the analysis. Indeed, among nine clinical studies published after 2002 and included in the meta-analysis, only three reported BAL PCR sensitivities of Ͻ70% (72, 129, 158) , with one of Ͻ60% (158) and none of Ͻ50%. On the other hand, in four studies, the sensitivity was higher than 90%. Interestingly, the same analysis provided evidence that the use of a commercial DNA extraction protocol is the most important factor for improved performance (122) , thus identifying a potential cause for discrepancies between results of different trials. Finally, two studies evaluated the performance of a nested PCR assay on CSF samples from patients with central nervous system (CNS) aspergillosis and reported a sensitivity of 100% and a specificity of 93% (9, 136) , thus showing that this assay has the potential to contribute to the diagnosis of this rare disease entity. However, given the relatively small number of patients involved in these studies, more trials are needed before one can safely reach a conclusion.
An additional point of consideration is the optimal time for sampling and the effect of antifungal treatment on PCR performance. Indeed, due to the limits of nonmolecular diagnostic methods, many patients at risk for IA receive prophylactic antifungal therapy, and understanding how this can affect PCR results could help to determine whether the method could be used to monitor the response to therapy or can serve only as a screening procedure. However, none of these questions can be answered appropriately without knowing the kinetics of DNA release during fungal growth. In an effort to elucidate this aspect of Aspergillus infection pathogenesis, Mennink-Kersten et al. investigated the release of different biomarkers during the in vitro growth of Aspergillus spp. and found that DNA is released only after mycelium breakdown, during nutrient starvation, and not during hyphal growth, in contrast to galactomannan antigen, which is released mainly during the logarithmic growth phase (175) . One could assume that antifungal treatment, by causing generalized mycelium breakdown, would lead to increased yields of the PCR assays, at least transiently, before fungal loads are significantly decreased. However, this hypothesis is undermined by reports from clinical studies and experimental models of IA, which show that PCR performance is negatively affected by antifungal treatment (132, 141, 143, 177) . One explanation for this paradox could be the fact that most DNA extraction protocols focus on methods of fungal cell lysis which can destroy free-floating fungal DNA, and thus render it undetectable (175) . Consequently, the use of an additional extraction setup to preserve free DNA could enhance PCR sensitivity. Indeed, in a recent study, Springer et al. used a new commercially available extraction protocol that includes both cellular and cell-free fungal DNAs and found significant improvements in sensitivity compared to an in-house extraction system, without affecting the specificity of the assay (178) . Another intriguing question is whether all classes of antifungals affect PCR results in similar ways. Researchers studying these effects on a rat inhalation model of IA found that the measured reduction of PCR sensitivity with antifungal therapy could be attributed only to posaconazole and caspofungin, not to amphotericin B (179) . However, other studies have failed to reach the same conclusion (141, 177) . Interestingly, a recent study evaluating the performance of PCR to diagnose IA by use of BAL fluid after at least one full daily dose of antifungal therapy showed that its performance was not significantly affected unless two or more antifungals were used to treat the patient (143) . This observation is very important when one considers that, in clinical practice, patients with prolonged fever and compromised immune responses often receive prophylactic antifungal regimens which consist of one antifungal agent, usually active against Candida spp., as they are the most common offenders. In such cases, the sensitivity of nonmolecular diagnostic methods is adversely affected, thus lowering the chance to start targeted treatment in patients with undiagnosed IA. Therefore, detection of Aspergillus spp. by BAL fluid PCR could be particularly useful for this population of patients.
Several studies in the recent literature have attempted to compare the diagnostic performances of PCR and galactomannan assays for Aspergillus spp. A recent meta-analysis compared the two diagnostic tests on BAL fluid samples and found that their performances were similar, without significant differences (180) , which is in agreement with findings from previous studies (163, 164) . Similarly, PCR and GM assays performed on serum samples have accuracies that are comparable to each other, although their accuracies are lower than the results obtained from BAL fluid (166) . Interestingly, a diagnostic strategy that combines these two tests, requiring at least one positive result for the diagnosis, seems to have a high sensitivity without sacrificing specificity (97% sensitivity and 97.5% specificity) (180) . Since invasive aspergillosis is a serious infection that is often treated empirically in high-risk groups to avoid detrimental outcomes, such a strategy could prove to be particularly useful and cost-effective for high-risk patients, as it could reduce unnecessary treatment without compromising patient safety (181) .
Finally, it is tempting to investigate the implications of PCR results on treatment and outcomes of IA. Many clinical trials evaluating the use of PCR to detect Aspergillus spp. in high-risk populations have reached the conclusion that consecutive positive PCR results are associated with higher mortality in cases of suspected IA (133, 141) , a phenomenon which is probably associated with the higher fungal burdens in this subset of patients, thus leading to larger amounts of circulating DNA. A more conclusive argument can be made for the potential of the method to guide empirical antifungal therapy. An early study suggested that the use of two consecutive positive PCR results to guide antifungal ther-apy in hematology patients could have led to a decrease in empirical antifungal agents of up to 37% (134) . However, due to the noninterventional study design, the researchers were unable to determine how this could affect patient survival. On the other hand, a novel randomized controlled trial with 240 hematologic malignancy patients from six Australian centers compared traditional and biomarker (galactomannan and PCR) diagnostic strategies to guide the use of antifungal agents in patients with hematologic malignancies and concluded that the biomarker strategy led to a significant (17%) decrease in empirical antifungal therapy without affecting survival (181) . Therefore, such a strategy could significantly reduce the inadvertent use of antifungal agents in patients who would not benefit from them.
Taking all the above into consideration, it becomes evident that PCR has the potential to play a decisive role in the diagnosis and management of Aspergillus sp. infections. However, due to the large number of PCR assays that, despite sharing the same core principles, differ in so many aspects of their performance, much effort should be given to implement a standardization that clinical practices can adopt. To this end, the European Aspergillus PCR Initiative (EAPCRI) studied the performances of different PCR assays and whole-blood preparation protocols for fungal DNA extraction and purification from spiked EDTA-anticoagulated blood samples (182) . The study was performed by 24 centers using 13 different PCR assays and showed that PCR performances were similar regardless of the type of PCR assay used. The only reasons for significant discrepancies were the use of an internal control to avoid false-positive findings and the DNA extraction protocol, with results favoring bead beating, use of red and white blood cell lysis buffers, and use of elution volumes of Ͻ100 l. Thus, the EAPCRI issued recommendations for optimal PCR performance from whole blood, with compliant centers being able to detect at least 50 conidia of Aspergillus spp. and achieving an average sensitivity and specificity of 88.7% and 91.6%, respectively. These results were corroborated by a follow-up study from the same group (183) . Importantly, a further effort to evaluate and standardize different PCR methods with serum samples was recently completed (171) . The panel investigated different PCR methods used by 23 centers on spiked serum samples and showed an overall sensitivity and specificity of 86.1% and 93.6%, respectively, and an ability to detect a threshold of 10 genomes/ml. Moreover, regression analysis of the results showed that larger serum volumes (Ͼ0.5 ml), elution volumes of Ͻ100 l, the use of an internal control, and the use of PCR targeting the internal transcriber spacer region of rDNA (159, 162) were associated with higher accuracy, while the use of primers targeting mitochondrial DNA (151, 154) adversely affected sensitivity. Finally, based on the findings of the aforementioned studies, the Aspergillus Technology Consortium created and validated an Aspergillus sp. DNA calibrator material that can be used to standardize nucleic acid-based diagnostic assays, thus improving interlaboratory comparisons of qualitative and quantitative results between different techniques (184) . Although the repercussions of these endeavors have yet to be realized in ensuing clinical trials, it is anticipated that they will reduce the inconsistencies observed in previous studies and will pave the way to large-scale implementation of Aspergillus sp. PCR.
Invasive candidiasis. Multiple studies have evaluated the performance of PCR tests for the diagnosis of invasive Candida infections in patient populations (4, 118, (185) (186) (187) (188) (189) (190) (191) (192) (193) (194) (195) (196) (197) (198) (199) (200) (201) (202) (studies are summarized in Table 5 ). The ranges of reported sensitivity and specificity values are 56.2 to 100% and 54 to 100%, respectively. However, most studies report higher sensitivity and specificity values, in the ranges of 80 to 100% and 90 to 100%, respectively. Importantly, the definitions of true-positive and true-negative results vary significantly among different reports. These differences should be considered fundamental, as accuracy values may change significantly depending on the way that each study handles cases of probable and possible invasive candidiasis. Interestingly, many studies show a tendency of PCR methods to detect Candida DNA in patients at high risk of invasive candidiasis with negative blood culture (187, 189, 202) . In some cases of discordant results between blood cultures and PCR, Candida spp. were isolated from the same population of patients, from another sterile site, thus indicating that the PCR result was in fact positive and proving the superiority of the assay over the traditional gold standard diagnostic test (187) . Indeed, a recent study analyzing PCR results from many clinical trials showed average sensitivity and specificity values of 95% and 92%, respectively, and indicated that PCR was able to detect 85% of cases of proven or probable invasive candidiasis, while blood cultures were positive in only 38% of the cases (203) .
Despite the promising reports of detection of Candida spp. by PCR, much effort should be made to standardize the method and decrease the inconsistencies between different tests. An important and ongoing debate is focused on the choice of specimen type on which to conduct the PCR test. Indeed, serum, whole blood, and plasma have all been used for Candida sp. DNA isolation (4, 185, 186 ). An in vitro study aiming to evaluate the kinetics of Candida sp. DNA release in blood fractions showed that most DNA is found in a cell-free form that remains in the plasma fraction after whole-blood centrifugation (204) . Interestingly, clinical studies comparing PCR analysis of serum with that of whole blood or plasma found that PCR on whole blood is significantly less sensitive than PCR on the other two types of specimens (195, 200) . This observation can be explained by the cumbersome purification and cell lysis steps associated with the use of whole blood for DNA extraction, which may decrease sensitivity by destroying some of the free circulating fungal DNA. To confound the ongoing argument, a recent meta-analysis of studies evaluating Candida sp. PCR on clinical specimens reached the exact opposite conclusion, that whole-blood PCR is associated with a better performance (203) . Notably, though, since this is only an indirect comparison, with different clinical samples and different PCR methods, and since the number of studies using whole blood that were included in the analysis greatly exceeded the number of studies using serum (43 versus 12) , the relevance of this comparison remains questionable. Importantly, the same analysis also showed that a higher performance was associated with the use of primers targeting the rRNA and P450 gene regions.
An alternative approach is to use PCR to identify Candida spp. directly from blood culture bottles (205) (206) (207) (208) . This method would significantly decrease the time for species identification from a positive blood culture, which can now reach 96 h (205). In fact, an early study showed that a multiplex real-time PCR assay was able to identify the isolated Candida spp. in less than 2 h, and the results were 100% concordant with results of nonmolecular methods (205) . These results were supported by later studies using different PCR assays (207, 208) . To understand the clinical significance of these findings, one should consider that some Candida spp., such as Candida glabrata, are associated with high rates of resistance to traditional antifungal azoles that are used as first-line agents in the (197) . The study reported a sensitivity of 87.5% for the PCR test for proven and probable cases of invasive candidiasis, while the sensitivity of blood cultures was limited to 50%, thus proving the relevance of this method. Importantly, both PCR and serum biomarkers, such as ␤-glucan, are valuable tools for the detection of not only candidemia but also deep-seated candidiasis, which is often missed by blood cultures. Indeed, in a recent prospective study, the sensitivity of blood cultures for patients with deep-seated Candida sp. infections was limited to 17%, whereas ␤-glucan assay and, even more so, PCR had superior performances, providing positive results for 62% and 88% of the patients, respectively (4). Similar to the case for invasive aspergillosis, the excellent negative predictive values of both these tests could prove to be particularly useful in the development of diagnostic algorithms for invasive candidiasis that could help to reduce the rate of unnecessary empirical antifungal therapy (210) .
Finally, the identification of specific gene mutations that can confer resistance to known antifungal agents has allowed for the development of PCR methods that can rapidly detect these mutations. Specifically, PCR methods for the detection of mutations in the FKS1 gene that confer resistance to echinocandins (211) or of EGR11 mutations or overexpression of pump genes, such as CDR1, CDR2, and MDR1 (212), have recently been described. All these experimental techniques come with the promise of much more rapid identification of resistant Candida infections than the case with traditional broth microdilution methods, thus permitting timely initiation of appropriate treatment and decreasing the rates of treatment failure (213) .
Other IFIs. As is the case with Aspergillus spp. and Candida spp., detection of fungal DNAs from other fungal species is a tempting method for diagnosis of many invasive fungal infections. Therefore, PCR has been studied as a potential method to diagnose infections such as Pneumocystis jirovecii pneumonia, mucormycosis, and even rarer fungal infections, such as coccidioidomycosis and scedosporidiosis. Especially in the case of PCP, PCR seems to be an excellent alternative to traditional methods. Indeed, Pneumocystis jirovecii cannot be cultured, and its detection is based on staining methods using respiratory specimens, which suffer from low sensitivity (214) . Consequently, many studies have evaluated the performance of PCR on respiratory specimens for PCP diagnosis, and the results seem promising, with sensitivity values as high as 100% (91, (215) (216) (217) (218) (219) (220) (221) (222) (223) (224) . However, in the case of PCP, colonization is a significant issue, with rates as high as 22% in high-risk populations (225) , and more importantly, since DNA is fairly stable, it is difficult to distinguish between active and previous infections (226) . Thus, the question arises about the clinical importance of identifying Pneumocystis jirovecii DNA in respiratory samples from such patients. Indeed, reports from traditional PCR assays indicate high rates of false positivity that can reach 46% (222) . In order to avoid this situtation, two different methods have been employed. The first uses reverse transcription-PCR to identify mRNAs of the organism, which are easily degradable and thus signify a viable pathogen (227) . An early pilot study evaluating the assay was disappointing, with a sensitivity and specificity of 67% and 100%, respectively, with BAL fluid samples (215) . However, a later study with a larger population of patients reported more promising findings, with a sensitivity and specificity of 100% and 87%, respectively, with BAL fluid (218) . This method, however promising, is still unable to discriminate colonization from infection. To overcome that obstacle, a second technique was developed that relies on the use of real-time PCR assays to quantify the number of DNA copies found in a specimen. Studies have shown that the mean concentration of DNA from BAL fluid samples can be manifold higher in infected individuals than in asymptomatic carriers (219) . Thus, many different real-time PCR assays have been developed and evaluated, with studies showing sensitivity values comparable to those of conventional PCR techniques and consistently higher than 80% (91, 216, 217, 220, 222, 224) . The real breakthrough, though, is found in the comparison of specificity values, with reports indicating a specificity of real-time PCR that can reach 98% and that is superior to those of conventional PCR techniques at cutoff points selected to not affect sensitivity (216) . Indeed, a recent meta-analysis of studies evaluating PCR for PCP diagnosis found an average sensitivity and specificity of 99% and 90%, respectively, with real-time PCR associated with a significantly higher specificity value (93%), thus highlighting the great potential of the assay for the diagnosis of this disease (228) .
Another fungal disease which might benefit from PCR diagnosis is the spectrum of mucormycosis. Four studies reported the development of PCR assays to diagnose the pathogens causing this disease (229) (230) (231) (232) . An early study focused on the identification of Rhizopus spp. from clinical specimens and reported promising results, although the number of specimens tested was too small to allow for a significant conclusion (230) . A later study evaluated two real-time PCR assays in an experimental rabbit model of pulmonary mucormycosis, and both performed well on BAL fluid and plasma samples, with one of them achieving a higher sensitivity than that of quantitative culture with BAL fluid (100% versus 67%) (231) . Other researchers investigated the performance of a different real-time PCR test for the detection of mucormycosis from culture isolates and concluded that the assay is useful for rapid and accurate detection of this infection (229) . In a more recent article, investigators from different sites evaluated a PCR method in a murine model of disseminated mucormycosis and found a high performance of the assay on paraffin-embedded tissue specimens (93% sensitivity for 30 slide cuts) and a 100% interlaboratory reproducibility (232) . Furthermore, a recent retrospective study of real-time PCR for mucormycosis concluded that this test, performed on serum, was able to accurately diagnose the infection in 9 of 10 patients at a time point that was 3 to 68 days earlier than diagnosis with histopathology or culture (109) .
Finally, PCR methods have also been developed and evaluated for detection of other fungal species, such as Scedosporium spp. (233), Cryptococcus spp. (234) , Coccidioides spp. (235) , and Fusarium spp. (236) , but the possibility for clinical implementation of these assays seems unlikely for the foreseeable future, either because serologic assays are already highly sensitive and specific, thus lowering the need for molecular techniques, as is the case for Cryptococcus spp. and Coccidioides spp. (95) , or because clinical evaluation of their performance has not yet been accomplished (233) .
Multiplex PCR. A different method used in molecular diagnostics of fungal infections is the use of a PCR that can detect a wide variety of fungi at once in the same specimen. The technique is fairly simple and is based on the use of primers specifically de-signed to amplify a region that is conserved among different fungal genera. The identification method is slightly more complex and is based either on sequencing of the amplified fragments of DNA or on the design of probes that bind to amplified fragments and have different melting temperatures, so they can be detected by melting curve analysis. This method can be combined with either standard, nested, or real-time PCR, and depending on the primer and probe design, it can detect either some (237) or all (238) fungal species. The method has been tested thoroughly for the ability to detect fungal species in tissue samples, with most reports showing promising results and a high concordance with traditional histopathology methods (239) (240) (241) . Indeed, the method appears to have great value in the case of culture-negative and histologically proven infection (242) . In such cases, PCR facilitates species identification, which cannot be achieved through microscopy but can serve an important role in guiding antifungal therapy. Multiplex PCR has also been tested as a method to detect fungal species in whole-blood (236, 238, (243) (244) (245) , serum (246) , or BAL fluid (247) samples from patients at high risk for IFIs. The results are variable, but most studies report superior sensitivities and specificities of Ͼ80% (236, 238, 243, 248) . Nonetheless, these methods suffer from the same inconsistencies as PCR analysis of Aspergillus spp. or Candida spp. and should undergo a thorough standardization process before clinical implementation. Moreover, an important problem in the case of patients who are at high risk for IFIs is that these patients are frequently colonized or infected by multiple microbial species at the same time, a fact that can confound the results of diagnostic assays and often leads to wrong diagnostic assumptions that can adversely affect care. Indeed, in a recent retrospective study of hematologic malignancy patients, 53% of patients were diagnosed as having probable IA, and 29% of those with proven IA were coinfected with other bacterial species (249) . A potential solution to this problem could be the use of a broad-range multiplex PCR that can detect a wide variety of both bacteria and fungi, known as the SeptiFast assay, which has been developed commercially and is being used as a method to identify the pathogen in cases of sepsis (250, 251) . Similarly, a multiplex assay that can rapidly identify Ͼ25 pathogens, including many Candida spp., and antibiotic resistance genes in positive blood cultures within 1 h, known as the FilmArray system, was recently developed and commercialized for use in the microbial laboratory (252) . However, due to their use in sepsis cases, where fungal infections, although possible, are unlikely, studies evaluating these methods to date report small numbers of fungal cases. Therefore, further research is needed to prove whether these tests would be useful for individuals at high risk for IFIs. Finally, broad-range PCR methods have the potential to be used as methods of rapid identification of the pathogen in cases of outbreaks. An interesting example of this technique was recently used in the case of an Exserohilum sp. meningitis outbreak caused by contaminated methylprednisolone injections (253). Using a broad-range PCR targeting the rDNA fragment, with subsequent DNA sequencing and matrix-assisted laser desorption ionizationtime of flight mass spectrometry (MALDI-TOF MS), researchers were able to rapidly identify the species from the patient specimens and the methylprednisolone vials, thus finding both the pathogen and the source of the infection (254) . Interestingly, in the same study, the investigators noted the importance of rapid freezing of the specimens in order to avoid destruction of free circulating fungal DNA by DNases.
Although still in need of standardization, PCR offers the promising potential of being able to identify the presence of fungal pathogens within human fluids, define the species, quantify the infection, and detect antimicrobial resistance markers. At the forefront of conditions that need to be optimized are nucleic acid isolation methods, primer selection, and fluid sampling. Eventual total automation will help with enhancing the reproducibility of this technique.
Novel Molecular Methods
A variety of other molecular methods have been designed and tested over the years, either as a supplement to improve the performance of PCR or as separate tests. For example, fluorescence in situ hybridization (FISH) is a technique that uses fluorescent probes to identify target areas on the genomes of microbial pathogens in human samples, which can then be detected by fluorescence microscopy (Fig. 1A) . This method has been used as an adjunct to culture (255) or PCR (256) and has been proven to have high accuracy for the identification of Candida sp. infections from blood culture bottles (255) . Furthermore, data from two studies, on coccidioidomycosis (257) and invasive fungal rhinosinusitis (258) , show that the method has a promising performance on frozen tissue sections, even in cases where cultures are not available or have not been performed.
Nucleic acid sequence-based amplification (NASBA) is a method very similar to PCR but differs in the sense that it amplifies mRNA by using an RNA polymerase instead of DNA, and it is isothermal (259) . Arguably, its ability to detect mRNA gives it the advantage of detecting active disease instead of latent or previous infection (260) , and its isothermal nature, coupled with the fact that RNA is less stable than DNA, could decrease the chance of contamination (261) . Despite its availability since 1991, it was not until 10 years later that Loeffler et al. evaluated the potential of this method as a diagnostic tool for invasive aspergillosis (261) . They reported a threshold for detection of 1 CFU per 100 l of whole blood. An early clinical trial followed up by evaluating the method on blood samples from 128 hematology patients with neutropenic fever and found 100% sensitivity and 63% specificity for patients with proven or probable IA (260) . In a later study, investigators developed and evaluated a real-time NASBA method on blood samples from 78 patients and reported a sensitivity and specificity of 100% and 43%, respectively (262) . The high sensitivities reported by both groups increase hopes for the future use of the method as a screening test for high-risk populations to rule out IA. Finally, the same group of researchers reported later that this method could also be used to predict the clinical outcome, as negative conversion of a previously positive assay was associated with significantly more survival in patients with IA (263) .
A different approach, MALDI-TOF MS, is based on mass spectrometry to identify the protein fingerprints of different microorganisms. By direct comparison of the spectral pattern of the organism in question with databases of known patterns from different microorganisms, it is possible to identify the detected microbe at the genus, species, and even strain levels (264) (Fig.  1B) . Despite the fact that this technique was first described 30 years ago, it was not until recently that the scientific community started to realize its potential. Indeed, in recent years, this method has created a revolution for microbiological laboratories (265) . Four commercial systems based on this method that are able to identify yeasts and mold species have been developed, and the first such system was recently cleared by the FDA for use in clinical microbiology laboratories. Studies evaluating their performances are promising, showing that this method is able to accurately and rapidly identify Candida spp. and Aspergillus spp. from positive cultures, with a high concordance (consistently Ͼ90%) in comparison to conventional methods (264, (266) (267) (268) (269) (270) (271) (272) (273) (274) (275) (276) (277) (278) . Furthermore, in some reports, MALDI-TOF MS seems to outperform traditional identification techniques (274, 278) . Notably, earlier MALDI systems used for fungal identification required a protein extraction step prior to the spectrometric analysis, whereas newer methods, such as the Vitek MS system, manage to overcome this by using a single deposit step that avoids formic acid lysis, thus making the technique faster and easier to use (274) . Moreover, a MALDI method to rapidly assess the caspofungin susceptibility of isolated yeast and Aspergillus species was recently described (279) and subsequently modified to reduce turnaround times (280) . This method, which is based on the identification of changes in the protein composition of fungal cells exposed to caspofungin, was designed as a much faster (3 h versus 24 h) alternative to the traditional CLSI method, with comparable results. Finally, a recent interventional study involving 501 patients with bacteremia or candidemia showed that MALDI-TOF combined with an antimicrobial stewardship team was able to decrease the time to organism identification, thus improving antimicrobial agent selection and patient outcomes (281) . It is therefore evident that given the indisputable and ever-growing evidence of its superior, easier, and faster performance, MALDI-TOF MS has the potential to essentially replace conventional methods for identification of fungal pathogens in the next few years. Note that an alternative technique that has the same physical basis is the coupling of PCR amplification with electrospray ionization mass spectrometry (PCR-ESI MS) (282) . However, due to the short period since its first development, data from clinical studies are still too immature to reach a valid conclusion about its clinical relevance (283) .
A novel spectroscopic approach that could potentially help in diagnosis of fungal pathogens is the use of surface enhanced resonance Raman spectroscopy (SERRS) (284) . This method employs specific sensors that can detect scattered light produced by DNA coupled with a specialized dye and placed against roughened surfaces consisting of metals such as gold or silver. In a pivotal study, researchers successfully combined a gold-nanowire SERRS sensor with a target recycling reaction to detect a variety of pathogenic fungi. In this method, the tested sample is combined with multiple DNA probes, each targeting a sequence specific to a different fungal pathogen. After binding of a probe to its complementary fungal DNA within the tested sample, an exonuclease with activity on double-stranded DNA (dsDNA) digests the probe. This step is repeated several times, until most or all probes from the fungal species found in the sample are digested. Finally, the scattered light from the remaining probes is measured by the SERRS sensor, and the missing probe reveals the fungal pathogen (Fig. 1C ). The technique was tested on eight clinical blood culture samples that were positive for fungi and resulted in findings that were 100% concordant with results from culture (285) . Although these results seem promising, prospective studies with larger patient populations are needed to establish the position of the method in clinical diagnosis.
Following a completely different idea, other investigators focused on the detection of human pathogens by using microscopic resonating cantilevers (286, 287) . These are microchips with surfaces that are able to bind microorganisms from a fluid that is directed to pass through them. To achieve that, the surfaces are coated with antibodies or other proteins that can bind to microbial membranes. After binding of the pathogen, the mass of the cantilever increases, leading to a decrease in its resonance frequency, which can easily be detected. Researchers used cantilevers coated with concanavalin A, fibronectin, and IgG immunoglobulins to detect Aspergillus niger and Saccharomyces cerevisiae and reported detection limits of 10 3 to 10 6 CFU/ml (288) . Although the approach seems intriguing, refinement of the technique to achieve lower detection thresholds and evaluation with clinical samples would be imperative before it can be considered useful.
Moreover, a different method that is based on a physical phenomenon that has been known for a long time but has only very recently been appreciated for its usefulness in pathogen identification is nuclear magnetic resonance (NMR) spectroscopy. The physical phenomenon on which it is based was described over 70 years ago (289) , and its applications in different domains, such as chemistry (290) and radiology (291) , are immense. However, it was not until 2001 that the method was first realized to be useful in the field of microbiology (292) . Soon thereafter, investigators found that this method has the potential to identify Candida spp. from blood cultures by statistically comparing the magnetic resonance spectra of fungi in question to known databases (293) . A novel approach that seems to be even more promising, though, is the combination of NMR spectroscopy with PCR to directly detect and identify Candida spp. from blood samples from patients at risk. In this technique, whole blood is subjected to PCR amplification of Candida sp. sequences, followed by hybridization to nanoparticles that elicit a T2 magnetic resonance (T2MR) signal (Fig. 1D) . Results from a preliminary study of the T2MR method are exciting, showing that it is able to reduce the time to result to an average of 2 h, in contrast to the 48-h average of blood cultures (294). The T2MR method was able to accurately isolate yeast species from retrospectively collected, blinded clinical specimens. Based on these groundbreaking preliminary findings, a new large-A laser beam is targeted to the mix. The laser beam is absorbed by the matrix, and part of the analyte-matrix mix is vaporized and ionized, creating a cloud of ionized proteins and matrix. This cloud subsequently is subjected to an electric field, which leads the particles to accelerate toward a detector. The mass and charge of each particle determine the time needed to reach the detector. This allows the mass spectrometer to determine the characteristics of the particles within the tested sample. Comparison of the produced spectral pattern against a standard database allows for identification of the microorganism in the sample. (C) Surface enhanced resonance Raman spectroscopy. The tested sample is placed on a rough surface, which helps to create scattered light. DNA probes coupled with specialized dyes that emit light are added to the sample. The probes then bind to the target DNA in the sample, and subsequently, a double-stranded DNA exonuclease is added to the mix and digests all bound probes, while the unbound probes, which are single stranded, are left indigested. Finally, the scattered light from the undigested probe is detected by a sensor and analyzed, thus identifying the DNA sequence of the digested probes. (D) T2 nuclear magnetic resonance. First, the target sequence of a microorganism that is found in the sample is amplified. Subsequently, DNA probes coupled with paramagnetic nanoparticles are added to the amplicon and are allowed to hybridize with the amplified sequence. This changes the T2 relaxation time of the nanoparticles, and the change is detected via magnetic resonance imaging, thus identifying the target. scale prospective trial is under way to validate the assay and evaluate its clinical performance.
Finally, a novel exciting technique that was recently proposed and evaluated on a murine model of candidemia focuses on detecting the pathogen by measuring the induced host immune response (295) . Specifically, based on previous reports that indicate that the host immune response differs in response to different pathogens (296) , the researchers developed a method that was able to successfully differentiate between the gene expression signatures of mice with candidemia and mice with bacteremia or no infection, thus providing an alternative to all traditional methods that target the characteristics of the invading microorganism.
CONCLUSIONS
It is undoubtedly true that current gold standards for IFI diagnosis are lacking in both sensitivity and rapidity, thus delaying treatment and undermining survival of patients at risk. This underscores the need for the development of faster and more accurate diagnostic tests. Although novel serologic and molecular methods for detection and identification of fungal pathogens have been developed and are showing the potential to replace traditional diagnostic assays, inconsistencies between different approaches limit their reproducibility and prohibit large-scale clinical implementation. Thus, much effort should be made to standardize these techniques and ensure their reliability in order to significantly improve our ability to detect and treat fungal pathogens in an effective and timely manner. With continued emergence of new methods, we are reminded that fungal diagnostics is still in its infancy, with much room for improvement and refinement. ACKNOWLEDGMENTS E.M. has received grant support from Astellas Pharma and T2 Biosystems and has served in an advisory board for Astellas Pharma. A.M.C. has received grant support from T2 Biosystems. All other authors report no potential conflicts.
